Regeneron(US:REGN)2025-01-13 22:14Business Performance & Key Products - Dupixent's global net sales reached $3.8 billion in Q3 2024, representing a 23% year-over-year increase, annualizing to over $15 billion[8] - EYLEA HD and EYLEA U S net sales totaled approximately $6 billion in 2024, a 1% increase compared to the previous year[14] - EYLEA HD U S net sales in 2024 were $12 billion, comprising 20% of the total EYLEA and EYLEA HD net sales[17] - LIBTAYO's worldwide net sales reached $850 million through the first nine months of 2024, a 36% increase year-over-year[23] Pipeline & Clinical Development - Itepekimab Phase 2 trial data showed a 42% reduction in exacerbations in former smokers with COPD compared to placebo[38] - Fianlimab combined with LIBTAYO in first-line metastatic melanoma showed a 57% overall response rate (ORR) and a 25% complete response (CR) rate in pooled proof-of-concept cohorts[55] - In a Phase 3 trial for adjuvant CSCC, LIBTAYO demonstrated a 68% reduction in the risk of disease recurrence or death compared to placebo (HR: 032, p < 00001)[52] - In relapsed/refractory multiple myeloma, linvoseltamab showed a 71% overall response rate (ORR) and a 50% complete response (CR) rate[68] Strategic Outlook - Regeneron anticipates the therapeutic categories it is addressing to exceed an aggregate of $220 billion in 2030[4] - The company plans to resubmit the BLA for odronextamab in relapsed/refractory follicular lymphoma in Q1 2025[67] - FDA approval for linvoseltamab in relapsed/refractory multiple myeloma is anticipated by mid-2025[68]